, has been with the team since September 2022. Follow her on Twitter 

Articles

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.

Repetitive Nerve Stimulation Exhibits Positive Association with Inpatient Diagnosis of Myasthenia Gravis

Videos

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

, has been with the team since October 2019. Follow him on Twitter 

Among a surveyed cohort of patients with myasthenia gravis, 75% reported that their work was impacted, and 27% of respondents claimed they lost wages as a result of MG.

Substantial Economic Burden Is Frequent in Myasthenia Gravis, Primarily Driven by Direct Costs

Neurology News Network for the week ending September 24, 2022. [WATCH TIME: 4 minutes]

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

Eplontersin Treatment Results in Reduction in Serum Transthyretin in Amyloidosis

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

NeurologyLive® Friday 5 — September 23, 2022

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.

Rozanolixizumab Continues to Show Efficacy, High Responder Rates in Myasthenia Gravis

The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]

CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation. 

Pooled Clinical Trial Data Suggests Antidrug Antibody Testing for Alglucosidase Alfa-Exposed Patients With Pompe Disease 

Matt Hoffman, Managing Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive 

 show, Second Opinion. Follow him on Twitter 

Podcasts

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Ambereen Mehta, MD, MPH.

All News

Latest News